<DOC>
	<DOCNO>NCT02489227</DOCNO>
	<brief_summary>This 3-part study compare CHS-1420 Humira patient chronic plaque psoriasis .</brief_summary>
	<brief_title>Comparison CHS-1420 Versus Humira Subjects With Chronic Plaque Psoriasis</brief_title>
	<detailed_description>This 55-week , randomize , double-blind , active-control , parallel group , multicenter , global study subject active , moderate severe , chronic PsO . The study consist 24 week administration blind study drug , divide Treatment Period 1 Treatment Period 2 , 23 week administration open-label CHS-1420 Follow-up visit 8 week last dose . Subjects meet inclusion/exclusion criterion stratify body mass index ( BMI ) , age randomize 1:1 receive CHS-1420 Humira Treatment Period 1 . Subjects assign CHS-1420 continue receive CHS-1420 Period 2 . Subjects assign Humira Period 1 randomly assign ( 1:1 ) either continue Humira Treatment Period 2 switch CHS-1420 Treatment Period 2 . All subject receive open label CHS-1420 Treatment Period 3 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female adult PsO diagnosis 6 month Active disease : PASI great equal 12 , Physician 's Static Global Assessment ( PSGA ) score great equal 3 ( base scale 05 ) , Body Surface Area ( BSA ) involve PsO great equal 10 % Forms psoriasis PsO Drug induce psoriasis Positive QuantiFERONtuberculosis ( TB ) Gold Test Presence significant comorbid condition Chemistry hematology value outside protocol specify range Major systemic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PsO</keyword>
</DOC>